CBIO Crescent Biopharma, Inc.
Healthcare$20.29+0.00%OpenMarket Cap: $559.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.43
P/S
48.12
EV/EBITDA
-2.42
DCF Value
$20.86
FCF Yield
-26.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-1372.9%
Net Margin
-1363.9%
ROE
-100.9%
ROA
-81.4%
ROIC
-88.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.0M | 100.0% | $-24.7M | $-23.3M | $— | — |
| Q4 null | $10.8M | 100.0% | $-91.5M | $-92.4M | $— | — |
| FY null | $10.8M | 100.0% | $-152.6M | $-153.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-25.9M | $-24.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-21.0M | $-21.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-14.2M | $-15.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-17.2M | $-17.9M | $— | — |
| FY null | $0.00 | NaN% | $-49.9M | $-48.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-11.2M | $-9.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-10.4M | $-10.1M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-11.1M | $-10.7M | $— | — |
| Q4 2023 | $10.0K | 100.0% | $-9.6M | $-9.1M | $-0.14 | — |